2,158
Views
8
CrossRef citations to date
0
Altmetric
Editorial

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

, ORCID Icon &
Pages 847-849 | Received 19 Mar 2017, Accepted 07 Jun 2017, Published online: 16 Jun 2017

References

  • Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994 Aug;117(Pt 4):759–765.
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83:278–286.
  • Sand IK, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014 Feb 3;PMID:24493475.
  • Davies F, Wood F, Brain KE, et al. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals’ experiences. Int J MS Care. 2016 Sep-Oct;18(5):257–264.
  • Oh J, O’Connor PW. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):220–229.
  • Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017 Apr 1;74(4):459–469.
  • Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
  • Shirani A, Zhao Y, Petkau J, et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon betatreatment. Biomed Res Int. 2015;2015:451912. DOI:10.1155/2015/451912
  • Presas S, Hervás-Garcia JV, Ramo-Tello C. Stopping disease modifying therapy in multiple sclerosis patients (P3.113). Neurology. 2016 April 5;86(16 Supplement):P3.113.
  • Siger M, Durko A, Nicpan A, et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011 Apr 15;303(1–2):50–52.
  • Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004 Aug; 56(2):303–306.
  • Kister I, Spelman T, Alroughani R, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1133–1137.
  • Bsteh G, Feige J, Ehling R, et al. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Mult Scler. 2016;1:1352458516675751.
  • Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):237–243.
  • Marziniak M, Meuth S. Current perspectives on interferon beta-1b for the treatment of multiple sclerosis. Adv Ther. 2014;31(9):915–931.
  • Hassoun L, Eisele J, Thomas K, et al. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Mult Scler Demyelinating Disord. 2016;1:10.
  • American Academy of Neurology (AAN). Annual meeting. emerging science session poster 009. Presented. 2016. April 19, 2016.
  • Kappos L, Bar-Or A, Cree B, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study. ECTRIMS Online Library. ECTRIMS 2016, September 2016;3(suppl): pp. 1–917.
  • Giovannoni G, Cutter G, Pia-Sormani M, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord. 2017;12:70–78.
  • Butler M, Forte ML, Schwehr N, et al. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Editors Rockville (MD): Agency for Healthcare Research and Quality (US). 2015 Apr. Report No.: 15 EHC012-EF.
  • Ziemssen T, Kern R, Thomas K. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurology. 2016;16:124.
  • Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine. 2016;14(1):81–81.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.